[{"id":"20ab3da1-4b1b-4645-a925-205f881a9a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432963","created_at":"2021-01-17T18:04:39.866Z","updated_at":"2024-07-02T16:35:14.012Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy","source_id_and_acronym":"NCT02432963","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • MSI","pipe":" | ","alterations":" TP53 mutation • TP53 expression • TP53 overexpression","tags":["TP53 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/14/2016","start_date":" 06/14/2016","primary_txt":" Primary completion: 12/04/2017","primary_completion_date":" 12/04/2017","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"75c79647-b107-47ed-9d39-fa812e55d7c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082641","created_at":"2021-01-25T18:52:15.415Z","updated_at":"2024-07-02T16:35:35.972Z","phase":"Phase 1/2","brief_title":"Neoadjuvant/Adjuvant Chemotherapy, Vaccine \u0026 Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer","source_id_and_acronym":"NCT00082641","lead_sponsor":"University of Nebraska","biomarkers":" TP53","pipe":" | ","alterations":" TP53 overexpression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • INGN 225"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 05/01/2009","primary_completion_date":" 05/01/2009","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2023-09-22"},{"id":"eac472e6-d913-41cb-be2a-e641cd27b30f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03824483","created_at":"2021-01-18T18:53:20.649Z","updated_at":"2024-07-02T16:35:36.679Z","phase":"Phase 2","brief_title":"Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)","source_id_and_acronym":"NCT03824483","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 overexpression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 02/22/2019","start_date":" 02/22/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-18"},{"id":"b4eb2ce4-ce5e-4719-a980-3012b29e1492","acronym":"","url":"https://clinicaltrials.gov/study/NCT02275039","created_at":"2021-01-18T10:42:22.245Z","updated_at":"2024-07-02T16:37:11.146Z","phase":"Phase 1","brief_title":"p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer","source_id_and_acronym":"NCT02275039","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation • TP53 expression • TP53 overexpression","tags":["TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • p53MVA"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 04/23/2018","primary_completion_date":" 04/23/2018","study_txt":" Completion: 04/23/2018","study_completion_date":" 04/23/2018","last_update_posted":"2018-04-30"},{"id":"2886963b-a9f6-4428-8e57-0ed8bae6fca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01191684","created_at":"2021-01-18T04:46:05.028Z","updated_at":"2024-07-02T16:37:19.347Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer","source_id_and_acronym":"NCT01191684","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 expression • TP53 overexpression","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e p53MVA"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2017-08-01"}]